A federal judge has approved a $150 million settlement by GlaxoSmithKline of a 33-member direct purchaser class action over allegations the drugmaker monopolized the market for its nasal spray Flonase.
On Friday, U.S. District Senior Judge Anita B. Brody of the Eastern District of Pennsylvania also approved the payment of $50 million in attorney fees for plaintiffs class counsel.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]